These include monoclonal antibodies binding circulating VEGF, such as bevacizumab, as well multiple different agents known as TKIs, which are active against receptor tyrosine kinases, including VEGFR, with sunitinib being the primary agent used in patients with pancreatic NETs [11]. This evidence concerns the gene KDR and pancreatic neuroendocrine tumor.